OBJECTIVE: This study investigated the potential synergistic effects of two inducers of apoptosis: the small molecule ABT-737 and arsenic trioxide (ATO). METHODS: Human gastric carcinoma cell lines SGC-7901 and MGC-803 were used to determine the effects of ABT-737 and ATO (alone or in combination) on cell proliferation and apoptosis in vitro. In vivo effects of these drugs were investigated in SGC-7901 solid tumours, grown in immunodeficient mice. RESULTS: ABT-737 and ATO inhibited proliferation and induced apoptosis in SGC-7901 and MGC-803 cells in concentration-and time-dependent manners, and showed a synergistic effect. ABT-737 disturbed the binding of B cell lymphoma (Bcl)-2 homologous antagonist killer and Bcl-extra large; ATO downregulated myeloid cell leukaemia (Mcl)-1 protein and upregulated Mcl-1short, the short splicing variant. ABT-737 and ATO significantly suppressed SGC-7901 xenograft growth, synergistically inhibited tumour growth and induced apoptosis in vivo. CONCLUSIONS:
Introduction
Gastric cancer remains the third most frequent cause of cancer deaths in men, worldwide. 1 In addition, over 70% of new cases and deaths occur in developing countries, where 80% of gastric cancer cases have reached a clinically advanced stage by the time of surgical exploration (meaning that curative surgery is no longer possible for these patients). 1, 2 Conventional adjuvant treatments have shown only modest effects on the survival of patients with advanced gastric cancer. 3 There is, therefore, an urgent need for novel drugs to treat this condition.
Overexpression of genes that encode the antiapoptotic members of the B cell lymphoma (Bcl)-2 family of proteins is a common feature of various cancer types, and is closely related to drug resistance and poor prognosis. 4 These antiapoptotic proteins XP Sun, X Zhang, C He et al. ABT-737, arsenic trioxide and gastric carcinoma cells have been recognized as rational targets for novel anticancer drugs. 4 ABT-737 is a smallmolecule drug that mimics the action of the proapoptotic Bcl-2 homology (BH)3-only proteins and serves as an inhibitor of Bcl-2/Bcl-extra large (Bcl-X L ). 5 ABT-737 binds and neutralizes the antiapoptotic proteins, thereby sequestering proapoptotic BH3 domain proteins, promoting the oligomerization of Bcl-2 homologous antagonist killer (Bak) and, ultimately, apoptosis of cancer cells. 5 The anticancer activity of ABT-737 (as a single agent or in combination with other agents) has been demonstrated in vitro and/or in vivo, in small cell lung cancer, 5 -7 acute myeloid leukaemia, 8 multiple myeloma, 9 chronic lymphocytic leukaemia, 10 acute lymphoblastic leukaemia, 11 and lymphoma. 12 To date, however, the effect of ABT-737 on gastric cancer has not been reported.
Some tumours seem to be resistant to ABT-737-induced apoptosis. 12 The major mechanism underlying resistance to ABT-737 is its inability to inactivate myeloid cell leukaemia-1 (Mcl-1) protein, which is another antiapoptotic member of the Bcl-2 family. 8, 12 The MCL1 gene is overexpressed in many types of cancer cells, 8,12 -14 including gastric cancer cells 14 and gastric cancer tissues. 15 High basal levels of Mcl-1 protein are associated with resistance to ABT-737. 8, 10, 16 Acquired resistance to ABT-737 is also associated with the upregulation of Mcl-1. 17 Downregulation of Mcl-1 (by chemical agents or RNA interference) has been shown to enhance the sensitivity of various cancers to ABT-737. 12,16 -21 One practical approach to improving the efficacy of ABT-737 is to combine it with agents that can overcome these resistance mechanisms, to restore the sensitivity of cancer cells to ABT-737.
Arsenic trioxide (ATO) has been widely employed to treat acute promyelocytic leukaemia (APL) since its original application at the First Affiliated Hospital of Harbin Medical University (Harbin, China) in the 1970s, 22 and it has more recently been used to treat a variety of solid tumours. 23 Mechanisms that might explain the antitumour cytotoxicity of ATO include its ability to induce cell apoptosis and differentiation, and to inhibit cell proliferation. 24 ATO has also been shown to induce the apoptosis of gastric cancer cells 25, 26 and to downregulate Mcl-1, thereby enhancing the ability of ABT-737 to kill myeloma cells. 27 These results suggest that these two inducers of apoptosis (ABT-737 and ATO) might work synergistically to induce gastric cancer cell apoptosis. The present study investigated the synergistic potential of ABT-737 and ATO to induce apoptosis in the human gastric carcinoma cell lines SGC-7901 and MGC-803, in vitro and in vivo. was initially dissolved in dimethylsulphoxide (DMSO) to make a stock ABT-737, arsenic trioxide and gastric carcinoma cells solution (20 mM); this was stored at -20°C. Antibodies used in this study included polyclonal rabbit anti-Bcl-2, rabbit anti-Mcl-1 and monoclonal mouse anti-Bcl-X L (Santa Cruz Biotechnology), polyclonal rabbit anti-Bak (Abcam ® , Cambridge, MA, USA), and polyclonal rabbit anticaspase-3, rabbit anticaspase-9 and goat anti-β-actin (Zhongshan Golden Bridge Biotechnology, Beijing, China).
Materials and methods

CELLS, ANIMALS, REAGENTS AND ANTIBODIES
ASSAY OF CELL PROLIFERATION IN RESPONSE TO TREATMENT
Cells were seeded into 96-well plates (5 × 10 3 cells/well) and cultured for 12 h at 37°C, as described above. Then, the medium was replaced with RPMI 1640 containing various concentrations of ATO (1, 2, 4 and 8 nM), ABT-737 (2.5, 5, 10 and 20 µM) or combinations of ATO and ABT-737, and cells were cultured for a further for 24, 48 
ASSAY OF CELL APOPTOSIS IN RESPONSE TO TREATMENT
Cells were incubated with various concentrations of ATO, ABT-737 or ATO + ABT-737, as described above, at 37°C for 24 h. They were then trypsinized (0.25 % w/v in 0.01 M PBS at 37°C for 5 min), washed three times with 0.01 M PBS and counted. Then, 1 × 10 6 cells were suspended in 100 µl binding buffer with 5 µl of annexin V and 5 µl of propidium iodide (PI) and incubated for 15 min at room temperature in the dark, according to the manufacturer's instructions (all reagents from Beijing Biosea Biotechnology, Beijing, China). The proportion of apoptotic cells was analysed by flow cytometry using a Beckman Coulter EPICS ® ALTRA™ II flow cytometer (Beckman Coulter, Brea, CA, USA), or viewed under a laser scanning confocal microscope (LSM-510 Meta; Carl Zeiss Jena, Jena, Germany). Early-stage apoptotic cells were stained green by annexin V, as these cells display phosphatidylserine on their outer surface membranes which is readily detectable by annexin V. 28 Late-stage apoptotic cells have nuclei that are stained red by PI: the plasma membrane becomes increasingly permeable during the later stages of apoptosis, allowing PI to move across the cell membrane and bind to DNA. 28
WESTERN BLOT ANALYSIS
Western blot methodology has been described previously. 28 Briefly, cells that had been incubated with ATO, ABT-737 or ATO + ABT-737 at various concentrations (described above) were lysed in protein lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China) and debris was removed by centrifugation at 12 000 g. The protein content was determined using a protein assay kit (Beyotime Institute of Biotechnology), and protein samples (each weighing 30 µg) were resolved by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred to polyvinylidene difluoride membranes. The membranes were blocked with 3% bovine serum albumin for 3 h at room temperature and incubated with the primary antibodies described above anti-β-actin, 1:500) overnight at 4°C. The membranes were then washed four times with Tris-buffered saline and 0.05% Tween 20 (TBST) buffer (pH 7.6) and incubated with appropriate alkaline phosphataseconjugated secondary anti bodies (antirabbit immunoglobulin [Ig]G, antimouse IgG and antigoat IgG, all purchased from Zhongshan Golden Bridge Biotechnology), at a dilution of 1:2500 for 2 h at room temperature. After being washed four times with TBST buffer, the membranes were developed with 5bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (Tiangen Biotech, Beijing, China). The density of each band was measured using a densitometric image analysis system (FR200; Furi, Shanghai, China) and compared with that of the internal control protein, β-actin.
COIMMUNOPRECIPITATION ASSAY OF BCL-X L AND BAK OLIGOMERIZATION
It has been shown that ABT-737 binds and neutralizes Bcl-X L , thereby promoting Bak oligomerization. 5 A commercial coimmunoprecipitation kit (Beyotime Institute of Biotechnology) was used to assess the effects of ABT-737 and ATO on the binding of Bcl-X L and Bak in vitro, in both SGC-7901 and MGC-803 cells. For Western blot analysis, cells that had been incubated with ABT-737 (5 µM) for 24 h were lysed and the protein content was determined, as described above. A total of 500 µg of protein, 2 µg of primary antibody, and 10 µl agarose beads from the coimmunoprecipitation kit that were conjugated to protein A/G (a recombinant fusion protein that combines the IgG binding domains of protein A and protein G) were mixed and rotated end-to-end overnight at 4°C. The beads were resuspended in loading buffer and subjected to SDS-PAGE and Western blotting analysis as described above.
CDI VALUE CALCULATIONS
To determine whether the effects of ATO and ABT-737 were synergistic, the coefficient of drug interaction (CDI) was calculated, as described previously. 29 
TUMOUR XENOGRAFT MODELS AND THERAPY SCHEDULE
All of the procedures and care administered to animals were approved by the Institutional Ethics Committee of the First Affiliated Hospital of Harbin Medical University, under a permit of animal use (No. SYXK20020009), and were compliant with the Experimental Animal Regulations of the National Science and Technology Commission, China. Mice were housed under standard conditions and had free access to water and food, under a 12-h light/12-h dark cycle in a room maintained at 18 -22°C and 50 -65% humidity. SGC-7901 cells (5 × 10 6 ) were subcutaneously inoculated into the right flank of BALB/c mice (H-2b). Tumour volume was measured using callipers and estimated according to the formula: π ⁄ 6 × a 2 × b, where a was the short axis, and b was the long axis. After 10 days, when the tumours had reached about 0.2 cm in diameter, the mice were randomly assigned to four groups (n = 8 per group), using a randomization schedule generated by the SAS ® software package, version 9.2 (SAS Institute Inc., Cary, NC, USA). The groups were: control; ABT-737; ATO; ABT-737 + ATO. They received, respectively: vehicle (1% DMSO, 99% 0.01 M PBS; pH 7.4); ABT-737 (50 mg/kg); ATO (2.5 mg/kg); ABT-737 (50 mg/kg) + ATO (2.5 mg/kg) intraperitoneally (i.p.) every 2 days. Drugs were dissolved in the vehicle solution. To standardize the experiments, each mouse received a similar volume of solution. After XP Sun, X Zhang, C He et al. ABT-737, arsenic trioxide and gastric carcinoma cells 15 days, the mice were euthanized and the solid SGC-7901 tumours were harvested, fixed with 4% paraformaldehyde, frozen in optimal cutting temperature compound and stored at -80°C.
IN SITU DETECTION OF APOPTOTIC CELLS
The methodology for the in situ detection of apoptotic cells has been described previously. 28 Briefly, frozen tumour sections (5 µm thick) were stained with terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) agent (Roche R&D Center [China], Shanghai, China) according to the manufacturer's instructions, and examined by fluorescence microscopy. The total number of apoptotic cells in 10 randomly selected fields was counted. The apoptosis index (%) was calculated according to the formula: number of apoptotic cells/total number of nucleated cells × 100.
STATISTICAL ANALYSES
All statistical analyses were performed using the SAS ® software package, version 9.2. Data were expressed as mean ± SD of experiments carried out in triplicate. Comparisons among multiple groups were made with a one-way analysis of variance followed by Dunnett's test. A P-value < 0.05 was considered to be statistically significant.
Results
Both gastric carcinoma cell lines produced Bcl-2, Bcl-X L and Mcl-1 protein, as shown by Western blot analysis ( Fig. 1A) . Untreated SGC-7901 cells produced a significantly higher level of Bcl-2 protein than MGC-803 cells (P < 0.001), whereas untreated MGC-803 cells had a significantly higher level of Mcl-1 protein than SGC-7901 cells (P < 0.001). There was no significant difference in the level of Bcl-X L between the two cell lines.
Treatment with ABT-737 resulted in significant inhibition of the proliferation of both SGC-7901 ( Fig. 1B) and MGC-803 ( Fig.  1C ) cells in concentration-and timedependent manners (P < 0.001 for both at 20 µM ABT-737 after 72 h). SGC-7901 cells were more sensitive to ABT-737 than MGC-803 cells.
Treatment with ATO significantly inhibited the proliferation of SGC-7901 ( Fig.  2A ) and MGC-803 ( Fig. 2B ) cells in a concentration-dependent manner (P < 0.001 at 8 nM ATO), and synergized with ABT-737 to increase inhibition of the proliferation of both types of gastric carcinoma cells. All the CDI values for the various concentrations of ATO and ABT-737 were < 1, indicating a synergistic effect of ATO in combination with ABT-737.
An optimal synergistic concentration of 4 nM for ATO and 5 µM for ABT-737, which had a CDI value of < 0.6 in both cell lines, was used for subsequent experiments. The combination of ABT-737 (5 µM) and ATO (4 nM) resulted in inhibition of cell proliferation of SGC-7901 and MGC-803 cells by 63% and 42%, respectively ( Fig. 2A  and 2B ).
Treatment with ABT-737 (5 µM) or ATO (4 nM) resulted in a significant increase in the rate of apoptosis of both SGC-7901 ( Fig. 3A ) and MGC-803 ( Fig. 3B ) cells compared with vehicle (P < 0.05 for ABT-737 and P < 0.001 for ATO). The combination of ABT-737 (5 µM) and ATO (4 nM) led to even higher rates of apoptosis in both SGC-7901 and MGC-803 cells, which were significantly higher than either ABT-737 or ATO alone (P < 0.001 for all comparisons). The CDI values for the combination of ABT-737 (5 µM) and ATO (4 nM) in SGC-7901 and MGC-803 cells were 0.53 and 0.62, respectively, indicating that ABT-737 + ATO had a synergistic effect in inducing the apoptosis of gastric carcinoma cells.
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Flow cytometry showed that the mean overall rates of apoptosis of SGC-7901 cells were 3.6%, 6.2%, 29.5% or 64.8% when they were treated with vehicle, ABT-737, ATO or ABT-737 + ATO, respectively (Fig. 3C, upper  panels) . The mean overall rates of apoptosis in MGC-803 cells were 4.8%, 6.7%, 19.3% and 29.8%, respectively (Fig. 3C , lower panels).
Apoptosis was also confirmed by annexin V/PI staining analysis using laser confocal scanning microscopy. As shown in Fig. 3D (SGC-7901 cells, upper panels; MGC-803 cells, lower panels), only a small number of The coimmunoprecipitation assay showed that ABT-737 treatment disturbed the binding of Bcl-X L and Bak in both SGC-7901 and MGC-803 cells (Fig. 4A ). Mcl-1 levels were sensitive to ATO treatment: at a concentration of 1 nM, ATO almost completely blocked the production of Mcl-1 protein, whereas levels of Mcl-1short (Mcl-1S), were upregulated by ATO treatment in both cell lines (Fig. 4B ). ABT-737 and ATO synergized to activate caspase-9 and caspase-3. Levels of cleaved caspase-9 and caspase-3 were upregulated by ABT-737 and ATO in both cell lines, whereas ABT-737 + ATO further increased the levels of cleaved caspase-9 and caspase-3 (Fig. 4C) .
Solid SGC-7901 gastric carcinoma xenograft tumours in the control group grew very quickly, reaching a mean ± SD volume of 1007.4 ± 112.3 mm 3 at 15 days (Fig. 5A) . In contrast, tumours treated with ABT-737 and ATO were significantly smaller than control tumours, reaching a mean ± SD volume of 648.6 ± 89.1 and 483.5 ± 71.5 mm 3 , respectively (P < 0.05 versus control for both comparisons). The combination of ABT-737 + ATO further suppressed tumour growth, such that tumours reached a mean ± SD volume of 287.2 ± 56.3 mm 3 , which was significantly smaller than the control tumours (P < 0.001) and significantly smaller than the tumours treated with ABT-737 or ATO monotherapy (P < 0.001 and P < 0.05, respectively). The CDI was 0.85, indicating that ABT-737 and ATO had significant synergistic effects in suppressing in vivo tumour growth.
The rate of apoptosis in vivo was assessed in solid SGC-7901 gastric carcinoma xenograft tumours harvested 15 days after treatment. Consistent with the in vitro data, compared with control tumours, those 50 µm 50 µm 50 µm 50 µm ABT-737, arsenic trioxide and gastric carcinoma cells treated with ABT-737 or ATO had a significantly increased rate of apoptosis (210% and 297% higher than control for each treatment, respectively; P < 0.05 or P < 0.001, respectively) ( Fig. 5B ). Tumours treated with ABT-737 + ATO had a significantly increased rate of apoptosis (583% higher) compared with control tumours (P < 0.001) and compared with tumours treated with ABT-373 or ATO alone (113% and 49% higher for each treatment, respectively; P < 0.001 and P < 0.05, respectively). The CDI was 0.77, indicating that ABT-737 and ATO had significant synergistic effects in inducing cell apoptosis in vivo. Representative photomicrographs of TUNEL-stained tumour sections from mice in the control, ABT-737, ATO and ABT-737 + ATO groups are shown in Fig. 5C .
Discussion
The present study demonstrated for the first time that ABT-737 and ATO -two inducers of apoptosis -can work synergistically to inhibit growth and induce apoptosis of gastric carcinoma cells, in vitro and in vivo. The mechanism accounting for this synergistic effect may be based on the downregulation of Mcl-1 protein by ATO, given that overexpression of the MCL1 gene leads to resistance to ABT-737. 8, 12 ABT-737 disturbed the binding of Bak and Bcl-X L and synergized with ATO to activate caspase-3 and caspase-9 in gastric carcinoma cells. These results warrant further investigation of the combination of ABT-737 and ATO for the treatment of gastric cancer. Resistance to apoptosis is a feature of cancer cells and is associated with tumorigenesis, progression, metastasis and drug resistance. 30 The Bcl-2 family consists of antiapoptotic proteins (Bcl-2, Bcl-X L , Bcl-2like protein 2, Mcl-1 and Bcl-2-related protein A1) and proapoptotic proteins. The proapoptotic proteins are classified into two main groups: multidomain proapoptotic proteins (Bak and Bax); and BH3-only proteins, including Bcl-2 interacting mediator of cell death (Bim), BH3 interacting domain death agonist, Bcl-2-associated death promoter, a proapoptotic BH3containing protein, Noxa, and p53 upregulated modulator of apoptosis. 31 The interaction of these proteins determines the survival or death of the cells. 31 Overexpression of antiapoptotic genes gives cancer cells the ability to survive and resist drug-induced apoptosis. The present study demonstrated that Bcl-2, Bcl-X L and Mcl-1 were present at detectable levels in two gastric carcinoma cell lines. These antiapoptotic proteins have become potential targets for novel anticancer drugs, and specific inhibitors of Bcl-2 are among this type of drug. 4 ABT-737 is a unique specific inhibitor of Bcl-2 as it mimics the proapoptotic BH3-only proteins and specifically inhibits the function of Bcl-2/Bcl-X L . 5, 13 By binding to the BH3 domain of Bcl-X L , ABT-737 releases Bak from the Bak/Bcl-X L complex, leading to activation of Bak 32 and triggering the intrinsic apoptotic pathway, i.e. activation of caspase-9 that in turn directly cleaves procaspase-3. 28 The present study showed that ABT-737 disturbed the binding of Bcl-X L to Bak in both SGC-7901 and MGC-803 gastric carcinoma cell lines, as demonstrated by a coimmunoprecipitation assay, and led to the activation of caspase-9 and caspase-3. ABT-737 has been shown to induce the apoptosis of various cancer cells, 5 -12 to increase the sensitivity of cancer cells to other chemotherapeutic agents and to help overcome chemotherapy resistance, 33, 34 indicating that ABT-737 is a promising anticancer drug.
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• Revised accepted 29 May 2012 Copyright © 2012 Field House Publishing LLP tumours, limiting its application in cancer chemotherapy. 12 The major mechanism of ABT-737 resistance is the upregulation of Mcl-1 in cancer cells. 8, 12 In support of this, the present study showed that, compared with SGC-7901 cells, MGC-803 cells were less sensitive to ABT-737-induced apoptosis and the inhibition of proliferation, which may be due to MGC-803 cells having higher intrinsic levels of Mcl-1. Thus, combining ABT-737 with agents that downregulate Mcl-1 might help to overcome resistance and restore the sensitivity of cancer cells to ABT-737.
The antiapoptotic factor Mcl-1 is located on the outer membrane of mitochondria and inhibits the release of cytochrome c through binding to Bak. 35 Following the discovery of Mcl-1, the short splicing variant, Mcl-1S, was discovered. Mcl-1S has an altered C-terminus compared with the full-length Mcl-1long, and dimerizes with Mcl-1 to exhibit proapoptotic properties. 36 The present study showed that ATO downregulated Mcl-1, upregulated Mcl-1S and synergized with ABT-737 to induce apoptosis in gastric carcinoma cells. These findings are supported by previous studies in which Mcl-1 downregulation enhanced the sensitivity of tumour cells to ABT-737. 10,15 -21 In summary, following the discovery of ATO as a new and promising treatment for various types of leukaemia (particularly APL) a large number of studies 23, 37, 38 have investigated its use in the treatment of solid cancers including gastric cancer. 39 The treatment effects of ATO were not comparable with the previous success obtained with APL: doses of ATO required were higher than those used to treat haematological malignancies, and were not clinically achievable without the risk of ATO-mediated side-effects. 37 Consequently, a search for agents that would increase the efficacy of ATO against lesssensitive solid tumours was initiated. 38 Thus, combining ABT-737 with ATO may be advantageous, as ABT-737 could be employed to reduce the dose of ATO required, sparing side-effects without impairing antitumour efficacy. Further investigation of this possible combination treatment for gastric cancer is warranted.
